Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

RCT (n=406) found addition of bevacizumab to platinum-based doublet chemotherapy improved progression free survival (11.8 vs 8.8 months, HR.51, 95%CI 0.41 to 0.65) in patients with platinum sensitive recurrent ovarian cancer treated with bevacizumab first line.

The Lancet Oncology